All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Ujvira 100mg Injection
Prescription Required
Salt Composition : Trastuzumab Emtansine
Manufacturer : ZYDUS CADILA
Origin of Medicine : India
1 Vial(s)
PAP Information : Buy 7, Get 1 Free. Contact us for latest updates.
Program Overview: ZYDUS CADILA, Patient Assistance Program (PAP), is dedicated to helping patients in need of Ujvira 100mg injection. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase 7 vials of Ujvira 100mg injection, and you will receive one free vial. Therefore, if eligible, you will have to pay only Rs. 2,07,039 for 8 Vials, which is Rs.25,880 per vial.
With MrMed's MRP discount of Rs. 6135 per vial and Zydus’s PAP program, the overall savings is over 79 thousand rupees per purchase.
Contact us for the latest updates on this exclusive offer.
Eligibility Criteria: To qualify for the Ujvira Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Trastuzumab emtansine 100mg from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Zydus can avail of it without having to purchase the medication from MrMed.
Patient Assistance Programs
Program Overview: ZYDUS CADILA, Patient Assistance Program (PAP), is dedicated to helping patients in need of Ujvira 100mg injection. The program aims to provide eligible patients with access to the medication at a more affordable cost.
Program Benefits: Purchase 7 vials of Ujvira 100mg injection, and you will receive one free vial. Therefore, if eligible, you will have to pay only Rs. 2,07,039 for 8 Vials, which is Rs.25,880 per vial.
With MrMed's MRP discount of Rs. 6135 per vial and Zydus’s PAP program, the overall savings is over 79 thousand rupees per purchase.
Contact us for the latest updates on this exclusive offer.
Eligibility Criteria: To qualify for the Ujvira Patient Assistance Program (PAP), you must meet specific criteria, including having a valid prescription for Trastuzumab emtansine 100mg from a medical oncologist and being an Indian patient with a valid identity card. Eligibility is determined based on the diagnosed condition and program-specific requirements.
Contact Information: If you have any questions or need assistance with the application process, our dedicated patient support team is here to help. You can reach us by phone at 89391 69999 or email us at [email protected].
Please note that MrMed is not involved in the PAP program. They offer free consultations to patients to provide information about the program. Patients eligible for the PAP program by Zydus can avail of it without having to purchase the medication from MrMed.
Introduction to Ujvira 100mg Injection
Ujvira 100mg Injection is a targeted therapy containing the active constituent trastuzumab emtansine. The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine on February 22, 2013, for treating patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and chemotherapy. This medication is not recommended for adolescents and children under 18. Before taking this medicine, it is vital to inform your doctor if you have any blood clot disorders, liver disorders, or allergies.
Uses of Ujvira 100mg Injection
Ujvira 100mg Injection is indicated for its use in the following conditions:
- Advanced and metastatic breast cancer
Therapeutic Effects of Ujvira 100mg Injection
Trastuzumab binds selectively to the HER2 receptors on breast cancer cells' surface, blocks them from receiving growth signals, and stops the cancer cell's growth. DM1 becomes active once the drug enters the cancer cells and helps stop cancer cell growth.
Interaction of Ujvira 100mg Injection with other drugs
Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional and vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications may interact with Ujvira 100mg Injection and cause undesirable side effects.
More Information about Ujvira 100mg Injection
- Keep Ujvira 100mg Injection out of sight and reach of children.
- Store between 2˚C and 8˚C.
How to consume Ujvira 100mg Injection
- Ujvira 100mg Injection shall either be administered before or after surgery.
- It will be given as an Intravenous infusion for 90 minutes, if well tolerated it shall be administered within 30 minutes for the next doses.
Safety Advices for Ujvira 100mg Injection
Pregnancy
Discuss with your physician before taking this Ujvira 100mg Injection if you are pregnant or think you might be pregnant. Do not take this medicine during the pregnancy unless advised by the doctor to take as it may cause to the unborn baby.
Breast Feeding
Avoid breastfeeding your baby while on the treatment with Ujvira 100mg Injection atleast for at least seven months after the final dose.
Lungs
Talk to your doctor if you have any lung conditions before starting treatment with Ujvira 100mg Injection.
Liver
You need to tell your physician if you have any liver disorders before starting Ujvira 100mg Injection as it requires dosage adjustment for severe liver impairment.
Alcohol
Consult your doctor to know if it is safe to consume alcohol while you are on treatment with Ujvira 100mg Injection.
Driving
Ujvira 100mg Injection can cause unusual tiredness and dizziness. Hence, it is advised to avoid driving or handling machinery during the treatment.
Side Effects of Ujvira 100mg Injection
Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.
Serious
- Heart Problems
- Allergic reactions
- Kidney problems
- Breathing difficulties
Common
- Fever
- Visual disturbances
- Nose bleeds or runny nose
- Hair loss
- Dizziness
- Nail disorders
- Weight loss
- Loss of appetite
- Bruising
- Dry mouth
- Liver inflammation
- Muscle pain
- Asthma/ lung disorders
Word of Advice
It is suggested to inform your doctor if you have a history of allergic reactions to Ujvira 100mg Injection to avoid life-threatening complications. If you have a history of lung disorder or breathing problems inform your doctor beforehand before the treatment commencement. Avoid planning for pregnancy and breastfeeding for a minimum of 7 months after the last dose. Monitor your heart parameters regularly during the treatment with Ujvira 100mg Injection as it may impact the functioning of heart.
FAQs
Q 1. Is Ujvira 100mg Injection used as a monotherapy in treating breast cancer?
Ujvira 100mg Injection is generally given along with the chemotherapy medication such as paclitaxel or docetaxel or platinum compunds. Sometimes, it is also given with hormonal agents for those patients with elevated hormonal status.
Q 2. How long does Ujvira 100mg Injection treatment last?
The length of Ujvira 100mg Injection treatment will depend on the patient's case, including the stage and type of breast cancer and their response to the medication. In some cases, the treatment may continue for several months or years.
Q 3. Can Ujvira 100mg Injection cause hair loss?
Hair loss is not a common side effect of Ujvira 100mg Injection, but some patients may experience thinning or loss of hair due to chemotherapy or other cancer treatments.
Q 4. Does Ujvira 100mg Injection cause heart problems?
Yes, Ujvira 100mg Injection can damage the heart muscles. Hence to prevent the worsening of symptoms, it is advised to do a heart check-up every 3 months and continue till 2-5 years after the treatment completion.
Fact Box of Ujvira 100mg Injection
Molecule name: Trastuzumab Emtesnsine | Therapeutic class: Anti-cancer |
Pharmacological class: HER2 inhibitor | Indications: 1. Breast cancer |
References
- Roche, Electronic Medicines Compendium (EMC), [Revised on Jan 2022] [Accessed on 6th May 2023], https://www.medicines.org.uk/emc/files/pil.3856.pdf
- Genentech Inc, [Revised on Feb 2021] [Accessed on 6th May 2023], https://www.gene.com/download/pdf/herceptin_prescribing.pdf
- Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
